Gene expression after asbestos exposure may explain development of malignant mesothelioma microbiologystudy

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of malignant pleural mesothelioma (MPM), a rare and aggressive cancer.

By analyzing public RNA-seq data through a comprehensive bioinformatics pipeline, scientists working with the Sbarro Health Research Organization (SHRO) have developed an in-depth view of the molecular mechanisms involved in asbestos-induced carcinogenesis.

The findings highlight both known and novel genes and pathways, providing valuable insights into the biological processes disrupted in exposed patients. This work contributes to ongoing efforts to define reliable diagnostic and prognostic biomarkers and lays the groundwork for future investigations and potential clinical applications in personalized approaches to MPM management.

The article, titled “From asbestos exposure to carcinogenesis: Transcriptomic signatures in malignant pleural mesothelioma,” describes a new study investigating differential gene expression in malignant pleural mesothelioma (MPM) associated with documented asbestos exposure, with the aim of identifying specific transcriptomic biomarkers that could support advances in precision medicine.

Published in Experimental and Molecular Pathology, the paper was a collaborative effort between teams led by Professor Antonio Giordano, M.D., Ph.D., Founder and Director of the SHRO and Professor at Temple University, and Professor Elisa Frullanti, Ph.D., Director of the Cancer Genomics & Systems Biology Lab and Professor of Genetics at the University of Siena.

The study was conducted within the Med Biotech Hub and Competence Center at the University of Siena, in collaboration with the SHRO and the Sbarro Institute for Molecular Medicine and Cancer Research at Temple University. Co-authors include Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angela Rina, Francesca Mari, and Maria Palmieri.

Using publicly available RNA sequencing datasets, the research team employed a comprehensive bioinformatics pipeline to perform differential gene expression and functional enrichment analyses.

The results identified a distinct set of differentially expressed genes (DEGs) in MPM patients with documented asbestos exposure. Many of these genes are involved in key biological processes such as ion homeostasis, oxidative stress response, and cellular component disorganization—hallmarks of asbestos-induced cellular damage that may play a role in tumor initiation and progression.

“This is not just about cataloging genes,” says Frullanti. “It’s about constructing a molecular roadmap of asbestos-induced cancer development. With further validation, this could translate into real-world clinical applications.”

The findings shed new light on the molecular mechanisms of MPM and offer a foundation for future research into predictive and prognostic biomarkers. By pinpointing specific transcriptomic changes, the study contributes to efforts in precision medicine and supports the development of improved diagnostic tools and potential therapeutic targets for this deadly disease.

“This type of precision medicine means that we are one step closer to identifying patients more likely to develop Malignant Pleural Mesothelioma,” says Giordano, “and we are closer to developing potential treatments.”

As the global incidence of mesothelioma continues to rise—due in part to the long latency period of asbestos exposure and ongoing environmental risks—this study represents a critical step toward more personalized and effective management strategies for patients.

Provided by
Sbarro Health Research Organization (SHRO)